Comprehensive Care for Patients With ADHD:
                                                                Pharmacologic Treatment for ADHD


                                                  
 

 CME/CE-Certified Newsletter 2
   

 

 

 

 

 

Comprehensive Care for Patients With ADHD: Pharmacologic Treatment for ADHD

 

CME/CE-Certified Newsletter 2

 

 

 

WELCOME

ADHD is a common psychiatric disorder, affecting 6% to 8% of children and about 4% of adults. It causes functional impairment in every aspect of a patient's life―in school, at work, and at home.

 

Fortunately, a number of effective treatments are available. Over the last decade, many new formulations have increased the range of treatment options. Longer-acting formulations facilitate treatment coverage all day and into the evening for patients who need to remain alert to drive, study, or work.

 

In this newsletter, Comprehensive Care for Patients With ADHD: Pharmacologic Treatment for ADHD, we describe the available medications and provide practical information on their use. We discuss patient and drug characteristics that must be considered when selecting treatment, as well as research on alternative medications that your patients may ask about. We also include references to clinical trials, allowing you to easily find more detailed information. We hope this newsletter helps you tailor treatments to the needs of your patients.

 

This newsletter is part of a Web-based, regularly updated informative series that is easily searched and provides links to more detailed sources. We invite you to send us your feedback so that we may help you enhance the care of your patients with ADHD.

 

Sincerely,

 

Timothy E. Wilens, MD, Editor

Associate Professor, Psychiatry

Harvard Medical School

Director, Substance Abuse Services

Pediatric Psychopharmacology Research Program

Massachusetts General Hospital

Boston, Massachusetts

 

Release date: September 2008   Expiration date: September 30, 2009

                                                                          

Estimated time to complete this activity: 1 hour

 

Method of Participation

Read this newsletter, complete the CME/CE Activity Evaluation and Request for Credit Form online, and receive your statement of credit immediately. Print your statement of credit. This activity is provided free of charge to participants.

 

Intended Audience

Psychiatrists, primary care physicians, and nurse practitioners

 

Accreditation/Designation of Credit Statements

Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Physicians

Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Family Physicians
This activity has been reviewed and is acceptable for up to 1 Prescribed credit(s) by the American Academy of Family Physicians. AAFP accreditation begins September 1, 2008. Term of approval is for one year from this date with option for yearly renewal.

Nurse Practitioners
Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner continuing education by the American Academy of Nurse Practitioners: AANP Provider Number 040309. This program has been approved for 1.0 contact hour of continuing education (which includes 1.0 hour of pharmacology).

Sponsorship and Support

 

Sponsored by:

Supported by an educational grant from:


 

Administered by:
 

 

Financial Disclosure Statements

In accordance with the ACCME's Standards for Commercial Support, all CME/CE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CE activity content over which the individual has control. Disclosures are as follows:

 

Larry Culpepper, MD, MPH―AstraZeneca, Forest Laboratories, Eli Lilly and Company, Neurocrine, Pfizer Inc, Wyeth (speakers bureau and/or consultant), Blue Cross Foundation of Massachusetts (grant/research support).

 

Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc, Eli Lilly and Company, Merck and Co., Inc., National Institute of Mental Health, National Institute on Drug Abuse, Novartis Pharmaceuticals Corporation, Ortho-McNeil Janssen Scientific Affairs, LLC, Shire (grant/research support, speakers bureau, and/or consultant).

 

The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.

 

Off-Label/Investigational Uses of Drugs/Medical Devices Disclosure

Participants are advised that this CME/CE activity will contain references to unlabeled/unapproved/investigational uses of drugs to treat patients with ADHD.

 

Disclaimer

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Veritas Institute for Medical Education, Inc. or McNeil Pediatrics, administered by Ortho-McNeil Janssen Scientific Affairs, LLC. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

 

Copyright © 2008 Veritas Institute for Medical Education, Inc. All rights reserved.

 

Editorial Board

 

Timothy E. Wilens, MD, Editor

Associate Professor, Psychiatry

Harvard Medical School

Director of Substance Abuse Services, Clinical and Research Programs

Pediatric Psychopharmacology Research Program

Massachusetts General Hospital

Boston, Massachusetts

 

Larry Culpepper, MD, MPH

Professor and Chair, Family Medicine

Boston University School of Medicine

Chief, Family Medicine

Boston Medical Center

Boston, Massachusetts

 

LEARNING OBJECTIVE

You will be able to select and titrate pharmacologic treatments that improve symptomatic behavior and cognitive functioning in adolescents and adults with ADHD.

 

1. Please indicate your practice type.

 

If Other, please specify:

2. How many years have you been practicing?

 

3. How many patients with ADHD do you see per week?

 

PREACTIVITY ASSESSMENT

Please select the best answer below:

1. When titrating pharmacologic treatment for ADHD, the dose can be increased as frequently as

 
Please indicate your level of agreement with the following statement.

2. Stimulant use should be avoided in patients who require high blood pressure medication to be normotensive.

 

 

Please provide your e-mail address:  
 



Click here to view references. Click again to close